ProQR Therapeutics Management
Management criteria checks 3/4
ProQR Therapeutics' CEO is Daniel de Boer, appointed in Feb 2012, has a tenure of 12.17 years. total yearly compensation is €2.44M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.87% of the company’s shares, worth $1.41M. The average tenure of the management team and the board of directors is 4.3 years and 6 years respectively.
Key information
Daniel de Boer
Chief executive officer
€2.4m
Total compensation
| CEO salary percentage | 21.5% |
| CEO tenure | 12.2yrs |
| CEO ownership | 0.9% |
| Management average tenure | 4.3yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01ProQR reports Q3 results
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €2m | €524k | -€28m |
| Sep 30 2023 | n/a | n/a | -€37m |
| Jun 30 2023 | n/a | n/a | -€54m |
| Mar 31 2023 | n/a | n/a | -€60m |
| Dec 31 2022 | €2m | €504k | -€64m |
| Sep 30 2022 | n/a | n/a | -€69m |
| Jun 30 2022 | n/a | n/a | -€61m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€61m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
| Sep 30 2018 | n/a | n/a | -€35m |
| Jun 30 2018 | n/a | n/a | -€40m |
| Mar 31 2018 | n/a | n/a | -€44m |
| Dec 31 2017 | €1m | €353k | -€44m |
Compensation vs Market: Daniel's total compensation ($USD2.60M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.
CEO
Daniel de Boer (40 yo)
12.2yrs
Tenure
€2,439,000
Compensation
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Chairman of Supervisory Board | no data | €150.00k | 0.52% € 841.5k | |
| Founder | 12.2yrs | €2.44m | 0.87% € 1.4m | |
| Chief Corporate Development Officer | 1.8yrs | €1.31m | 0.57% € 920.0k | |
| Co-Founder & Chief Scientific Officer | 12.2yrs | €34.00k | no data | |
| Chief Financial Officer | 1.4yrs | no data | no data | |
| Chief People & Operations Officer | 4.3yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Junior Financial Controller | no data | no data | no data |
4.3yrs
Average Tenure
53yo
Average Age
Experienced Management: PRQR's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Chairman of Supervisory Board | 10.3yrs | €150.00k | 0.52% € 841.5k | |
| Independent Member of Supervisory Board | 9.6yrs | €126.00k | 0% € 0 | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Supervisory Board Member | less than a year | €271.00k | 0.033% € 53.0k | |
| Independent Member of Supervisory Board & Chairman of Scientific Advisory Board | 7.8yrs | €132.00k | 0.076% € 123.1k | |
| Independent Supervisory Board Member | 4.9yrs | €127.00k | 0% € 0 | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member Scientific Advisory Board | 6yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Supervisory Board Member | less than a year | €84.00k | 0% € 0 |
6.0yrs
Average Tenure
62.5yo
Average Age
Experienced Board: PRQR's board of directors are considered experienced (6 years average tenure).